Determining a treatment plan

No two migraines are the same

Different migraines require different treatment approaches. Migraine is a debilitating disease that can be further complicated when certain symptoms are present.

 

Some patients may need several acute medication options to address their varying migraine pain and associated symptoms.

49%

of patients reported that they wake up with migraines in a national survey of medically diagnosed adult migraine patients (n=500).1

Consider the route of administration

The American Headache Society recommends a non-oral triptan formulation for the following patient types:2

Morning
migraine

Rapid-onset
migraine

Migraine
with nausea

For your patients who need a fast-acting option in their migraine toolbox, Zembrace® SymTouch® is a powerful choice.3,4

Zembrace® SymTouch® is for acute treatment of migraine with or without aura in adults.

Want more information?

Sign up today to learn more about Zembrace® SymTouch®.

    Note: This registration form is intended for healthcare providers only.

    *All fields required.


    Privacy Policy and Authorization

    By clicking the submit button below, you consent to the use by Tonix Medicines, Inc. and its third parties of the information you have provided to periodically send you information about Zembrace® SymTouch® or other products and promotions.

    Tonix Medicines, Inc. and its third parties use the information you provide for legitimate business purposes only and will not sell, share, or otherwise distribute your personal information to third parties. By joining, you acknowledge that your consent to receive automated messages is not required as a condition to purchase goods and services.


    References:

    1. Migraine Patient Survey. Slide Player. http://player.slideplayer.com/3/1372890/#. Accessed 2021.
    2. Rothrock JF, Friedman DI. Information for health care professionals: triptan therapy for acute migraine. American Headache Society. https://americanheadachesociety.org. Accessed 2021.
    3. Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: February 2021.
    4. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.